Header Logo

Connection

Lynn Morris to Epitopes

This is a "connection" page, showing publications Lynn Morris has written about Epitopes.
Connection Strength

4,073
  1. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. J Virol. 2018 09 01; 92(17).
    View in: PubMed
    Score: 0,590
  2. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,394
  3. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol. 2007 Oct; 81(19):10769-76.
    View in: PubMed
    Score: 0,274
  4. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
    View in: PubMed
    Score: 0,179
  5. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell. 2019 12 12; 179(7):1636-1646.e15.
    View in: PubMed
    Score: 0,161
  6. Common helical V1V2 conformations of HIV-1 Envelope expose the a4ß7 binding site on intact virions. Nat Commun. 2018 10 26; 9(1):4489.
    View in: PubMed
    Score: 0,149
  7. Measuring the ability of HIV-specific antibodies to mediate trogocytosis. J Immunol Methods. 2018 12; 463:71-83.
    View in: PubMed
    Score: 0,148
  8. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. PLoS Pathog. 2018 01; 14(1):e1006825.
    View in: PubMed
    Score: 0,142
  9. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. J Virol. 2017 09 15; 91(18).
    View in: PubMed
    Score: 0,138
  10. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381).
    View in: PubMed
    Score: 0,134
  11. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog. 2017 01; 13(1):e1006148.
    View in: PubMed
    Score: 0,132
  12. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. J Virol. 2016 Nov 15; 90(22):10220-10235.
    View in: PubMed
    Score: 0,130
  13. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
    View in: PubMed
    Score: 0,121
  14. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 2015 Apr; 23(4):204-11.
    View in: PubMed
    Score: 0,115
  15. Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J. 2013 Dec 02; 10:347.
    View in: PubMed
    Score: 0,106
  16. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
    View in: PubMed
    Score: 0,106
  17. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med. 2012 Jul 30; 209(8):1469-79.
    View in: PubMed
    Score: 0,097
  18. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011; 6(9):e23532.
    View in: PubMed
    Score: 0,092
  19. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011 Oct; 85(19):9998-10009.
    View in: PubMed
    Score: 0,090
  20. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011 Apr; 85(7):3128-41.
    View in: PubMed
    Score: 0,087
  21. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006 Jul; 3(7):e255.
    View in: PubMed
    Score: 0,064
  22. Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proc Natl Acad Sci U S A. 2024 Jan 23; 121(4):e2308942121.
    View in: PubMed
    Score: 0,054
  23. Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. PLoS Pathog. 2022 09; 18(9):e1010450.
    View in: PubMed
    Score: 0,049
  24. HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. J Virol. 2022 07 27; 96(14):e0032422.
    View in: PubMed
    Score: 0,048
  25. Neutralizing antibody responses to HIV-1 infection. IUBMB Life. 2002 Apr-May; 53(4-5):197-9.
    View in: PubMed
    Score: 0,047
  26. Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nat Commun. 2022 02 16; 13(1):903.
    View in: PubMed
    Score: 0,047
  27. The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin a4ß7 and promotes cellular activation and infection. Proc Natl Acad Sci U S A. 2020 12 22; 117(51):32566-32573.
    View in: PubMed
    Score: 0,043
  28. Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathog. 2019 09; 15(9):e1008005.
    View in: PubMed
    Score: 0,040
  29. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. J Virol. 2019 03 15; 93(6).
    View in: PubMed
    Score: 0,038
  30. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nat Commun. 2018 10 08; 9(1):4136.
    View in: PubMed
    Score: 0,037
  31. Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to a4ß7. PLoS Pathog. 2018 08; 14(8):e1007278.
    View in: PubMed
    Score: 0,037
  32. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0,033
  33. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016 Mar; 12(3):e1005520.
    View in: PubMed
    Score: 0,031
  34. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011 Aug; 85(15):7719-29.
    View in: PubMed
    Score: 0,022
  35. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011 May; 85(10):4828-40.
    View in: PubMed
    Score: 0,022
  36. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009 Sep; 5(9):e1000598.
    View in: PubMed
    Score: 0,020
  37. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 2009 May 10; 387(2):414-26.
    View in: PubMed
    Score: 0,019
  38. Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J Virol. 2009 Jan; 83(1):470-8.
    View in: PubMed
    Score: 0,019
  39. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol. 2008 Feb; 82(4):1860-9.
    View in: PubMed
    Score: 0,018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.